Details of the Drug Combination

General Information of Drug Combination (ID: DCRJJBK)

Drug Combination Name
MK-1775 SNX-2112
Indication
Disease Entry Status REF
Invasive ductal carcinoma Investigative [1]
Component Drugs MK-1775   DM3WDZ5 SNX-2112   DMB5A80
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: T-47D
Zero Interaction Potency (ZIP) Score: 3.76
Bliss Independence Score: 0.79
Loewe Additivity Score: 2.03
LHighest Single Agent (HSA) Score: 2.96

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of MK-1775
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
MK-1775 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Wee1-like protein kinase (WEE1) TTJFOAL WEE1_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
MK-1775 Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Phosphorylation [5]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Response To Substance [5]
------------------------------------------------------------------------------------
Indication(s) of SNX-2112
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [4]
SNX-2112 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Heat shock protein 90 alpha (HSP90A) TT78R5H HS90A_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
SNX-2112 Interacts with 14 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Inhibitor of nuclear factor kappa-B kinase subunit alpha (CHUK) OTLF4ZB1 IKKA_HUMAN Decreases Expression [7]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [7]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [7]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Decreases Expression [7]
Endoplasmin (HSP90B1) OT02XLBR ENPL_HUMAN Decreases Expression [7]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Expression [7]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Expression [7]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Expression [7]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [7]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Decreases Expression [7]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [7]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [7]
Heat shock protein 75 kDa, mitochondrial (TRAP1) OTNG0L8J TRAP1_HUMAN Decreases Expression [7]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DC9F99K OVCAR3 Investigative [8]
Adenocarcinoma DCJRSKJ COLO320DM Investigative [8]
Adenocarcinoma DCR5JTN DLD1 Investigative [8]
Adenocarcinoma DCB8F4X HCT116 Investigative [8]
Adenocarcinoma DC0TTTP SW-620 Investigative [8]
Amelanotic melanoma DCNDPZY A2058 Investigative [8]
Ewing sarcoma-peripheral primitive neuroectodermal tumour DC5488Q ES2 Investigative [8]
Germ cell tumour DC3DD90 PA1 Investigative [8]
Large cell lung carcinoma DCNMHLY NCI-H460 Investigative [8]
Malignant melanoma DC1XKAO RPMI7951 Investigative [8]
Malignant melanoma DCPFJWS SKMEL30 Investigative [8]
Mesothelioma DCPHBT5 MSTO Investigative [8]
Non small cell carcinoma DCRP09O SKMES1 Investigative [8]
Ovarian endometrioid adenocarcinoma DCIQ3QC A2780 Investigative [8]
Prostate carcinoma DCJ2KSI VCAP Investigative [8]
Breast and ovarian cancer syndrome DC1YOJN UWB1289 Investigative [1]
Breast and ovarian cancer syndrome DCK7EQI UWB1289+BRCA1 Investigative [1]
Breast carcinoma DCZJPC2 OCUBM Investigative [1]
Carcinoma DC58QG1 EFM192B Investigative [1]
Colon adenocarcinoma DCTN716 LOVO Investigative [1]
Colon carcinoma DCUD15Z RKO Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 21 DrugCom(s)

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7702).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Heat shock protein 90: inhibitors in clinical trials. J Med Chem. 2010 Jan 14;53(1):3-17.
5 Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Clin Cancer Res. 2014 Aug 15;20(16):4274-88. doi: 10.1158/1078-0432.CCR-13-2858.
6 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
7 The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-B and disruption of mitochondria-dependent pathways. Chem Biol Interact. 2013 Sep 5;205(1):1-10. doi: 10.1016/j.cbi.2013.06.007. Epub 2013 Jun 15.
8 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.